1 / 21

Early Management of NSTE-ACS: From the ED to the Cath Lab

Early Management of NSTE-ACS: From the ED to the Cath Lab. Main Limitations of UFH. Fondaparinux*. Bivalirudin. Otamixaban. Early Management of NSTE-ACS: From the ED to the Cath Lab. Evaluation of Chest Pain. ACCF/AHA Recommendations for Initial Management of UA/NSTEMI.

stephanie-hess
Download Presentation

Early Management of NSTE-ACS: From the ED to the Cath Lab

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Early Management of NSTE-ACS:From the ED to the Cath Lab

  2. Main Limitations of UFH

  3. Fondaparinux*

  4. Bivalirudin

  5. Otamixaban

  6. Early Management of NSTE-ACS:From the ED to the Cath Lab

  7. Evaluation of Chest Pain

  8. ACCF/AHA Recommendations for Initial Management of UA/NSTEMI

  9. ESSENCE: TIMI Risk Score and Treatment Effect

  10. TIMACS: Early vs Delayed Intervention Stratified by GRACE Score

  11. SYNERGY: Postrandomization Crossover From Enoxaparin to Unfractionated Heparin

  12. Otamixaban: In Clinical Development for Management of ACS

  13. SEPIA-ACS TIMI 42: Otamixaban vs UFH + Eptifibatide in High-Risk NSTEMI ACS

  14. TAO: Study Design

  15. References

  16. References (cont)

  17. References (cont)

  18. References (cont)

More Related